<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-27298" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Histology, Plasma Cells</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Allen</surname>
            <given-names>Hunter C.</given-names>
          </name>
          <aff>Creighton University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sharma</surname>
            <given-names>Poonam</given-names>
          </name>
          <aff>Creighton University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hunter Allen declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Poonam Sharma declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>30</day>
          <month>12</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-27298.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Plasma cells are differentiated B-lymphocyte white blood cells capable of secreting immunoglobulin or antibodies. They play a significant role in the adaptive immune response, being the main cells responsible for humoral immunity. Without their presence, an individual is said to have agammaglobulinemia and is highly susceptible to recurrent infection. Here, the hematopoietic lineage, structure, and function of plasma cells, along with the clinical presentations arising from improper plasma cell growth and development, are reviewed.</p>
      </sec>
      <sec id="article-27298.s2" sec-type="Function">
        <title>Function</title>
        <p>After antigenic stimulation, plasma cells develop from antigen-activated B lymphocytes in lymphoid organs, such as the bone marrow, spleen, and lymph nodes. Blimp-1, IRF4, and XBP-1 transcription factors are known to be essential for the differentiation of mature B cells into plasma cells.<xref ref-type="bibr" rid="article-27298.r1">[1]</xref><xref ref-type="bibr" rid="article-27298.r2">[2]</xref>&#x000a0;BLIMP-1 and XBP-1 are often viewed as key regulators of plasma cell differentiation, with Blimp-1 working upstream of XBP-1.<xref ref-type="bibr" rid="article-27298.r3">[3]</xref><xref ref-type="bibr" rid="article-27298.r4">[4]</xref><xref ref-type="bibr" rid="article-27298.r5">[5]</xref><xref ref-type="bibr" rid="article-27298.r6">[6]</xref>&#x000a0;Plasma cell differentiation is also linked to the activation of the unfolded protein response (UPR) signaling pathway.<xref ref-type="bibr" rid="article-27298.r5">[5]</xref><xref ref-type="bibr" rid="article-27298.r7">[7]</xref>&#x000a0;UPR activation aids in the plasma cell&#x02019;s ability to adapt continually to an ever-changing milieu. However, the UPR&#x02019;s function is still under investigation; the belief is that the UPR plays a role in monitoring immunoglobulin concertation and modulating or suppressing immunoglobulin secretion.<xref ref-type="bibr" rid="article-27298.r8">[8]</xref></p>
        <p>The most immature blood&#x000a0;cell of a plasma cell&#x000a0;lineage is the&#x000a0;plasmablast.&#x000a0;Plasmablasts can proliferate and secrete small amounts of antibodies. The terminally differentiated or mature plasma cells are non-proliferating, are much larger than B cells, and can secrete large amounts of antibodies. During their lifespan of 2&#x000a0;to 3 days, they continuously synthesize and secrete antibodies with specificity for the antigen that stimulated the plasma cell precursor to proliferate and differentiate. Estimates are that a single plasma cell can secrete hundreds to thousands of antibody molecules per second, a remarkable measure of the power of the immune response for combating pathogens. Plasma cells, as antibody factories, are important contributors to humoral immunity.</p>
        <p>Though the production and secretion of antibodies were long thought to be the sole functions of plasma cells, recent studies indicate plasma cell involvement in immune response regulation. Research has found that plasma cells inhibit the development of follicular T-helper cells within this capacity.<xref ref-type="bibr" rid="article-27298.r9">[9]</xref>&#x000a0;Mice devoid of plasma cells, via knock-out of the BLIMP-1 gene, expressed elevated levels of follicular T-helper cells, which, in turn, produce IL-21, a protein critical for the processes of affinity maturation, germinal center longevity and function, and B-lymphocyte terminal differentiation.<xref ref-type="bibr" rid="article-27298.r1">[1]</xref><xref ref-type="bibr" rid="article-27298.r10">[10]</xref>&#x000a0;The elevated IL-21 resulting from lacking plasma cells could alter germinal center activity and fates or B-lymphocyte levels. In contrast, limited follicular T-helper cells and IL-21 appear to elevate a competitive milieu for active germinal center physiology, resulting in enhanced B-lymphocyte affinity and maturation. These findings suggest that an antigen-specific negative feedback loop exists, modulating plasma cell production, thus mitigating unnecessary and potentially pathological excess plasma cell numbers.<xref ref-type="bibr" rid="article-27298.r9">[9]</xref><xref ref-type="bibr" rid="article-27298.r10">[10]</xref></p>
      </sec>
      <sec id="article-27298.s3" sec-type="Histochemistry and Cytochemistry">
        <title>Histochemistry and Cytochemistry</title>
        <p>All plasma cells, albeit normal or malignant, are distinguished by their expression of CD38 and CD138.<xref ref-type="bibr" rid="article-27298.r11">[11]</xref>&#x000a0;The former catalyzes the synthesis and hydrolysis of cyclic ADP-ribose, resulting in the maintenance of intracellular calcium levels.<xref ref-type="bibr" rid="article-27298.r12">[12]</xref>&#x000a0;In contrast, CD138, syndecan-1, allows the plasma cell to attach to extracellular matrix proteins. Recent research has found that in addition to its role in plasma cell adhesion, CD138 plays a further role in acting as a co-receptor for epithelial growth factor (EGF), particularly in the context of multiple myeloma.<xref ref-type="bibr" rid="article-27298.r11">[11]</xref><xref ref-type="bibr" rid="article-27298.r12">[12]</xref>&#x000a0;Though malignant plasma cells express CD38 and CD138 alongside their normal, non-malignant counterparts, a distinguishing characteristic unique to malignant plasma cells is the loss of CD19 expression alongside the possible aberrant expression of CD56, a marker characteristic of natural killer (NK) cells.<xref ref-type="bibr" rid="article-27298.r11">[11]</xref><xref ref-type="bibr" rid="article-27298.r13">[13]</xref> It bears mention, however, that not all myeloma cells express CD56.</p>
        <p>An additional noteworthy marker of plasma cells is CD79a. The protein is critical in B-lymphocyte antigen signal transduction and overall B-lymphocyte development and stabilization.<xref ref-type="bibr" rid="article-27298.r14">[14]</xref>&#x000a0;Though CD79a is present in the cytoplasm of precursor B-lymphocytes and mature, differentiated plasma cells, its aberrant loss of expression has been noted in certain samples of plasma cell neoplasms.</p>
      </sec>
      <sec id="article-27298.s4" sec-type="Microscopy, Light&#x0000d;&#x0000a;">
        <title>Microscopy, Light
</title>
        <p>Plasma cells vary in size from 14 to 20 micrometers. They are round-to-ovoid cells containing abundant deep blue cytoplasm with a pale perinuclear area corresponding to the Golgi apparatus. They have a round, eccentrically placed nucleus with coarse chromatin arranged in a clock face (art wheel) pattern (see <bold>Image.</bold> Plasma Cells).<xref ref-type="bibr" rid="article-27298.r15">[15]</xref>&#x000a0;Most plasma cells are uninucleate; few are binucleate or multinucleate. They may contain cytoplasmic inclusions called Russell bodies or multiple spherical inclusions packed in their cytoplasm (Mott, grape, or morular cells). Russell bodies and the inclusions of Mott cells are dilated endoplasmic reticulum cisternae containing condensed immunoglobulins.</p>
      </sec>
      <sec id="article-27298.s5" sec-type="Microscopy, Electron&#x0000d;&#x0000a;">
        <title>Microscopy, Electron
</title>
        <p>Electron microscopy reveals that the plasma cells contain an eccentric round nucleus with condensed chromatin and a well-developed nucleolus. The nuclear membrane-associated chromatin gives the nuclei of mature plasma cells a cartwheel appearance in histologic sections. The cytoplasm contains parallel arrays of rough endoplasmic reticulum, cytoplasmic fibrils, and numerous polymorphic mitochondria. The cytoplasm also contains a Golgi complex immediately adjacent to the nucleus. Intracytoplasmic inclusions&#x02014;elliptical, round, or needle-like crystalline&#x02014;are present. A significant accumulation of immunoglobulins forms these inclusions.</p>
      </sec>
      <sec id="article-27298.s6" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Deviation from proper plasma cell proliferation can lead to a number of clinical pathologies, which are classified as plasma cell neoplasms and plasma cell immunodeficiency.&#x000a0;</p>
        <p>Plasma cell neoplasms are characteristically an aberrant proliferation of clonal plasma cells producing monoclonal, heavy-chain, class-switched immunoglobulin, referred to as M-protein.<xref ref-type="bibr" rid="article-27298.r16">[16]</xref>&#x000a0;Given the excessive proliferation and associated findings induced by such proliferation, plasma cell neoplasms can be classified into several specified pathological states. Determination of the extent of neoplasm involves a complete diagnostic evaluation, which includes the following specific tests and observations: complete CBC with differential; serum protein electrophoresis (to evaluate for M protein); immunofixation (to determine amount and type of immunoglobulin); serum-free light chain analysis; complete skeletal survey (to assess for the presence of lytic lesions); and a bone marrow biopsy (to determine the percentage of clonal plasma cells and potential cytogenetic analysis).<xref ref-type="bibr" rid="article-27298.r17">[17]</xref></p>
        <p>
<bold>Plasma Cell Neoplasms</bold>
</p>
        <p>
<bold>MGUS</bold>
</p>
        <p>Monoclonal gammopathy of undetermined significance, or MGUS, is the least severe manifestation of plasma cell neoplasm. MGUS classifies as a clonal population of plasma cells secreting immunoglobulin, though serum M-protein concentration does not exceed 3 g/dL.<xref ref-type="bibr" rid="article-27298.r18">[18]</xref>&#x000a0;Likewise, the clonal plasma cells do not exceed 10% of the bone marrow. Patients are often asymptomatic, and many patients with MGUS do not progress into malignancy. Research has shown that the prevalence of MGUS affects 1%&#x000a0;to 2% of the population in the United States and Europe.<xref ref-type="bibr" rid="article-27298.r19">[19]</xref>&#x000a0;Men are more often affected than women, and the incidence increases with age. Further, research has identified a higher prevalence in individuals of African descent.<xref ref-type="bibr" rid="article-27298.r20">[20]</xref></p>
        <p>Immunofixation studies of monoclonal proteins indicate that approximately 70% of MGUS cases are IgG, 15% are IgM, 12% are IgA, and 3% are biclonal.<xref ref-type="bibr" rid="article-27298.r21">[21]</xref>&#x000a0;Contingent on immunoglobulin type, MGUS is often classified into&#x000a0;2 main types with distinct potential clinical progression. Patients with IgM MGUS may progress to lymphoplasmacytic lymphoma or Waldenstr&#x000f6;m macroglobulinemia. In contrast, the progression of non-IgM MGUS cases manifests as smoldering myeloma or multiple myeloma.</p>
        <p>
<bold>Smoldering Myeloma</bold>
</p>
        <p>As plasma cells continue to proliferate aberrantly, an individual may progress beyond the criteria of MGUS, a stage defined clinically as smoldering myeloma. In contrast to MGUS, serum M-protein levels are equal to or greater than 3 g/dL, and clonal plasma cells&#x000a0;comprise 10% to 59% of the bone marrow.<xref ref-type="bibr" rid="article-27298.r18">[18]</xref>&#x000a0;By definition, a patient with smoldering myeloma does not present with CRAB lesions.&#x000a0;CRAB lesions demonstrate calcium elevation, renal inefficacy, anemia, and bone disease (lytic lesion(s)). They are a potential manifestation seen in multiple myeloma, as explained in the following subsection.</p>
        <p>Similar to MGUS, the criteria for smoldering myeloma manifest asymptomatically.<xref ref-type="bibr" rid="article-27298.r22">[22]</xref>&#x000a0;In contrast to MGUS, however, individuals with smoldering myeloma are significantly more likely to progress to the stage of symptomatic multiple myeloma: the rate of progression from smoldering myeloma to multiple myeloma is 10% annually for the first&#x000a0;5 years; 3% annually for the next&#x000a0;5 years; and 1% each year onward.<xref ref-type="bibr" rid="article-27298.r22">[22]</xref></p>
        <p>
<bold>Multiple Myeloma</bold>
</p>
        <p>The most severe presentation of plasma cell neoplasm is that of multiple myeloma. Though similar to smoldering myeloma in having serum M-protein concentrations of at least 3 g/dL, multiple myeloma criteria require the presence of at least&#x000a0;1 additional characteristic. Such include the presence of&#x000a0;1 or more CRAB lesions, bone marrow clonal plasma cells exceeding 60%, a serum-free light chain ratio equal to or greater than 100, and at least&#x000a0;1 focal lesion detected in MRI.<xref ref-type="bibr" rid="article-27298.r18">[18]</xref>&#x000a0;</p>
        <p>Multiple myeloma represents approximately 10% of all hematopoietic neoplasms.<xref ref-type="bibr" rid="article-27298.r19">[19]</xref>&#x000a0;Symptoms vary from individual to individual and range from focal, non-specific signs to systemic involvement. Commonly presenting symptoms include anemia, usually normochromic and normocytic; bone pain, especially in the chest and back; renal failure (elevated creatinine); hypercalcemia; fatigue, infection, and weight loss.<xref ref-type="bibr" rid="article-27298.r19">[19]</xref>Unfortunately, multiple&#x000a0;myeloma&#x000a0;is often incurable, ultimately resulting in death attributable to infection or renal failure. Median survival ranges from 2.5 to 5 years and is highly variable.</p>
        <p>
<bold>Other Plasma Cell Neoplasms</bold>
</p>
        <p>Amyloidosis is classified as the deposition of immunoglobulin light chain fibrils from clonal plasma cells, often of lambda composition. Such can occur independently or as sequelae of MGUS, smoldering myeloma, or multiple myeloma.<xref ref-type="bibr" rid="article-27298.r19">[19]</xref>&#x000a0;Deposition of amyloid fibrils most commonly occurs in the kidney, heart, nervous, and gastrointestinal systems. A positive Congo Red stain confirms the presence of amyloid, manifest by a red/pink color under light microscopy and fluorescing as apple-green&#x000a0;birefringence when polarized. Additional plasma cell neoplasms include solitary plasmacytoma of bone and extraosseous plasmacytoma.</p>
        <p>
<bold>Plasma Cell Deficiencies</bold>
</p>
        <p>Counter to the preceding disorders, characterized by excessive plasma cells or their byproducts, common variable immunodeficiency (CVID) results from inadequate plasma cell numbers. Reduced levels of IgG, IgA, or IgM establish the diagnosis of the disorder.<xref ref-type="bibr" rid="article-27298.r23">[23]</xref>&#x000a0;Specifically, CVID is noted by an IgG level of &#x0003c; 400 mg/dL. The lack of immunoglobulin results in an increasingly significant susceptibility to bacterial infections. Further, individuals with CVID are prone to several chronic pathologies, including chronic lung disease, inflammatory bowel disease, autoimmune disorders, and lymphoid hyperplasia. As this diagnosis remains with an individual throughout his or her lifetime, antibody titer to common pathogens (ie,&#x000a0;<italic toggle="yes">Haemophilus influenzae</italic>, MMR, varicella, and pneumococcus) should have consistent testing.<xref ref-type="bibr" rid="article-27298.r23">[23]</xref>&#x000a0;If IgG levels decrease beyond 200 mg/dL, immunoglobulin replacement therapy is recommended.</p>
        <p>In addition to CVID, over 100 primary immunodeficiencies are attributable to improper B-lymphocyte development or function, including improper immunoglobulin production. X-linked agammaglobulinemia (XLA) is characterized by a mutant <italic toggle="yes">BTK</italic> gene (Bruton&#x02019;s tyrosine kinase), inhibiting pre-B cell formation.<xref ref-type="bibr" rid="article-27298.r24">[24]</xref>&#x000a0;The result is a diminished number of mature B-lymphocytes, including plasma cells, and reduced immunoglobulin production and secretion. Given XLA&#x02019;s inheritance, males are almost exclusively affected. In contrast, selective IgA deficiency (SIGAD), the most common primary immunodeficiency, affects males and females equally.<xref ref-type="bibr" rid="article-27298.r24">[24]</xref>&#x000a0;Though the specific mutation associated with SIGAD is not yet fully understood, the disease is known to present in a familial pattern, and the notion of multiple mutations causing SIGAD is under investigation. As implied in the name, patients with selective IgA deficiency lack IgA in the serum and mucosa; IgM and IgG levels are normal. Therefore, the condition appears due to improper isotype switching to IgA or improper IgA-secreting B cell maturation.<xref ref-type="bibr" rid="article-27298.r24">[24]</xref>&#x000a0;Given the sheer amount of additional primary immunodeficiencies attributable to B-lymphocytes and plasma cells, a continual understanding of these cells&#x02019; physiology is crucial for properly advancing the health sciences.</p>
      </sec>
      <sec id="article-27298.s7">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27298&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27298">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/27298/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=27298">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-27298.s8">
        <fig id="article-27298.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Plasma Cells. Top left: Numerous plasma cells are shown displaying eccentric nucleus and pale perinuclear area in the cytoplasm. Occasional binucleate plasma cells are present in the center of the field. H&#x00026;E &#x000d7;10 magnification. Top Right: Plasma cells with prominent pale perinuclear area in the cytoplasm corresponding to the Golgi apparatus. H&#x00026;E &#x000d7;20 magnification. Bottom Left: A round, eccentrically placed nucleus with coarse chromatin arranged in clock face pattern is characteristic of plasma cells. H&#x00026;E &#x000d7;100 magnification under oil immersion. Bottom Right: Some plasma cells contain intracytoplasmic inclusions called Russell bodies. H&#x00026;E &#x000d7;100 magnification under oil immersion. Contributed by P Sharma, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pjimage" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-27298.s9">
        <title>References</title>
        <ref id="article-27298.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shapiro-Shelef</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>KI</given-names>
              </name>
              <name>
                <surname>McHeyzer-Williams</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Liao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>McHeyzer-Williams</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Calame</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Blimp-1 is required for the formation of immunoglobulin secreting plasma cells and pre-plasma memory B cells.</article-title>
            <source>Immunity</source>
            <year>2003</year>
            <month>Oct</month>
            <volume>19</volume>
            <issue>4</issue>
            <fpage>607</fpage>
            <page-range>607-20</page-range>
            <pub-id pub-id-type="pmid">14563324</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27298.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Klein</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Casola</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cattoretti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Lia</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mo</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ludwig</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rajewsky</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dalla-Favera</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination.</article-title>
            <source>Nat Immunol</source>
            <year>2006</year>
            <month>Jul</month>
            <volume>7</volume>
            <issue>7</issue>
            <fpage>773</fpage>
            <page-range>773-82</page-range>
            <pub-id pub-id-type="pmid">16767092</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27298.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shaffer</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>KI</given-names>
              </name>
              <name>
                <surname>Kuo</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Hurt</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Rosenwald</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Giltnane</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Calame</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Staudt</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program.</article-title>
            <source>Immunity</source>
            <year>2002</year>
            <month>Jul</month>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>51</fpage>
            <page-range>51-62</page-range>
            <pub-id pub-id-type="pmid">12150891</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27298.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reimold</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Iwakoshi</surname>
                <given-names>NN</given-names>
              </name>
              <name>
                <surname>Manis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vallabhajosyula</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Szomolanyi-Tsuda</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gravallese</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Friend</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Grusby</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Alt</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Glimcher</surname>
                <given-names>LH</given-names>
              </name>
            </person-group>
            <article-title>Plasma cell differentiation requires the transcription factor XBP-1.</article-title>
            <source>Nature</source>
            <year>2001</year>
            <month>Jul</month>
            <day>19</day>
            <volume>412</volume>
            <issue>6844</issue>
            <fpage>300</fpage>
            <page-range>300-7</page-range>
            <pub-id pub-id-type="pmid">11460154</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27298.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iwakoshi</surname>
                <given-names>NN</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Vallabhajosyula</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Otipoby</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Rajewsky</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Glimcher</surname>
                <given-names>LH</given-names>
              </name>
            </person-group>
            <article-title>Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1.</article-title>
            <source>Nat Immunol</source>
            <year>2003</year>
            <month>Apr</month>
            <volume>4</volume>
            <issue>4</issue>
            <fpage>321</fpage>
            <page-range>321-9</page-range>
            <pub-id pub-id-type="pmid">12612580</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27298.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shaffer</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Shapiro-Shelef</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Iwakoshi</surname>
                <given-names>NN</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Qian</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Rosenwald</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hurt</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Petroulakis</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sonenberg</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yewdell</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Calame</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Glimcher</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Staudt</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation.</article-title>
            <source>Immunity</source>
            <year>2004</year>
            <month>Jul</month>
            <volume>21</volume>
            <issue>1</issue>
            <fpage>81</fpage>
            <page-range>81-93</page-range>
            <pub-id pub-id-type="pmid">15345222</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27298.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gass</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Gifford</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Brewer</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>Activation of an unfolded protein response during differentiation of antibody-secreting B cells.</article-title>
            <source>J Biol Chem</source>
            <year>2002</year>
            <month>Dec</month>
            <day>13</day>
            <volume>277</volume>
            <issue>50</issue>
            <fpage>49047</fpage>
            <page-range>49047-54</page-range>
            <pub-id pub-id-type="pmid">12374812</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27298.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cenci</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sitia</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Managing and exploiting stress in the antibody factory.</article-title>
            <source>FEBS Lett</source>
            <year>2007</year>
            <month>Jul</month>
            <day>31</day>
            <volume>581</volume>
            <issue>19</issue>
            <fpage>3652</fpage>
            <page-range>3652-7</page-range>
            <pub-id pub-id-type="pmid">17475256</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27298.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pelletier</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>McHeyzer-Williams</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Urich</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fazilleau</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>McHeyzer-Williams</surname>
                <given-names>MG</given-names>
              </name>
            </person-group>
            <article-title>Plasma cells negatively regulate the follicular helper T cell program.</article-title>
            <source>Nat Immunol</source>
            <year>2010</year>
            <month>Dec</month>
            <volume>11</volume>
            <issue>12</issue>
            <fpage>1110</fpage>
            <page-range>1110-8</page-range>
            <pub-id pub-id-type="pmid">21037578</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27298.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Hao</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>BY</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>YX</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Function and dysfunction of plasma cells in intestine.</article-title>
            <source>Cell Biosci</source>
            <year>2019</year>
            <volume>9</volume>
            <fpage>26</fpage>
            <pub-id pub-id-type="pmid">30911371</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27298.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bataille</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>J&#x000e9;go</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Robillard</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Barill&#x000e9;-Nion</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Harousseau</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Moreau</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Amiot</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pellat-Deceunynck</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy.</article-title>
            <source>Haematologica</source>
            <year>2006</year>
            <month>Sep</month>
            <volume>91</volume>
            <issue>9</issue>
            <fpage>1234</fpage>
            <page-range>1234-40</page-range>
            <pub-id pub-id-type="pmid">16956823</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27298.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van de Veen</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Stanic</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wirz</surname>
                <given-names>OF</given-names>
              </name>
              <name>
                <surname>Jansen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Globinska</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Akdis</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Role of regulatory B cells in immune tolerance to allergens and beyond.</article-title>
            <source>J Allergy Clin Immunol</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>138</volume>
            <issue>3</issue>
            <fpage>654</fpage>
            <page-range>654-665</page-range>
            <pub-id pub-id-type="pmid">27596706</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27298.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pellat-Deceunynck</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Barill&#x000e9;</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Puthier</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rapp</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Harousseau</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Bataille</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Amiot</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Adhesion molecules on human myeloma cells: significant changes in expression related to malignancy, tumor spreading, and immortalization.</article-title>
            <source>Cancer Res</source>
            <year>1995</year>
            <month>Aug</month>
            <day>15</day>
            <volume>55</volume>
            <issue>16</issue>
            <fpage>3647</fpage>
            <page-range>3647-53</page-range>
            <pub-id pub-id-type="pmid">7543019</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27298.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tanaka</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ichimura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Takata</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Morito</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tamura</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kondo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ohara</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yanai</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sakai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yoshino</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Frequent downregulation or loss of CD79a expression in plasma cell myelomas: potential clue for diagnosis.</article-title>
            <source>Pathol Int</source>
            <year>2009</year>
            <month>Nov</month>
            <volume>59</volume>
            <issue>11</issue>
            <fpage>804</fpage>
            <page-range>804-8</page-range>
            <pub-id pub-id-type="pmid">19883431</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27298.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bortnick</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Murre</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Cellular and chromatin dynamics of antibody-secreting plasma cells.</article-title>
            <source>Wiley Interdiscip Rev Dev Biol</source>
            <year>2016</year>
            <season>Mar-Apr</season>
            <volume>5</volume>
            <issue>2</issue>
            <fpage>136</fpage>
            <page-range>136-49</page-range>
            <pub-id pub-id-type="pmid">26488117</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27298.r16">
          <label>16</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Kaseb</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Durer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fazal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Babiker</surname>
                <given-names>HM</given-names>
              </name>
            </person-group>
            <chapter-title>Plasma Cell Cancer</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2022</year>
            <month>9</month>
            <day>26</day>
            <pub-id pub-id-type="pmid">29939690</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27298.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ghobrial</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Landgren</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>How I treat smoldering multiple myeloma.</article-title>
            <source>Blood</source>
            <year>2014</year>
            <month>Nov</month>
            <day>27</day>
            <volume>124</volume>
            <issue>23</issue>
            <fpage>3380</fpage>
            <page-range>3380-8</page-range>
            <pub-id pub-id-type="pmid">25298034</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27298.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rajkumar</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Dimopoulos</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Palumbo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Blade</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Merlini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mateos</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hillengass</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kastritis</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Richardson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Landgren</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Paiva</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Dispenzieri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>LeLeu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zweegman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lonial</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rosinol</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zamagni</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Jagannath</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sezer</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Kristinsson</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Caers</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Usmani</surname>
                <given-names>SZ</given-names>
              </name>
              <name>
                <surname>Lahuerta</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Johnsen</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Beksac</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cavo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Goldschmidt</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Terpos</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kyle</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Durie</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Miguel</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.</article-title>
            <source>Lancet Oncol</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>15</volume>
            <issue>12</issue>
            <fpage>e538</fpage>
            <page-range>e538-48</page-range>
            <pub-id pub-id-type="pmid">25439696</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27298.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Castillo</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Plasma Cell Disorders.</article-title>
            <source>Prim Care</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>43</volume>
            <issue>4</issue>
            <fpage>677</fpage>
            <page-range>677-691</page-range>
            <pub-id pub-id-type="pmid">27866585</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27298.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Landgren</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Gridley</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Turesson</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Caporaso</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Goldin</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Baris</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fears</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Hoover</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Linet</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States.</article-title>
            <source>Blood</source>
            <year>2006</year>
            <month>Feb</month>
            <day>01</day>
            <volume>107</volume>
            <issue>3</issue>
            <fpage>904</fpage>
            <page-range>904-6</page-range>
            <pub-id pub-id-type="pmid">16210333</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27298.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kyle</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Therneau</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Rajkumar</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Offord</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Larson</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Plevak</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Melton</surname>
                <given-names>LJ</given-names>
              </name>
            </person-group>
            <article-title>A long-term study of prognosis in monoclonal gammopathy of undetermined significance.</article-title>
            <source>N Engl J Med</source>
            <year>2002</year>
            <month>Feb</month>
            <day>21</day>
            <volume>346</volume>
            <issue>8</issue>
            <fpage>564</fpage>
            <page-range>564-9</page-range>
            <pub-id pub-id-type="pmid">11856795</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27298.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kyle</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Remstein</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Therneau</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Dispenzieri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kurtin</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Hodnefield</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Larson</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Plevak</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Jelinek</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Fonseca</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Melton</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Rajkumar</surname>
                <given-names>SV</given-names>
              </name>
            </person-group>
            <article-title>Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.</article-title>
            <source>N Engl J Med</source>
            <year>2007</year>
            <month>Jun</month>
            <day>21</day>
            <volume>356</volume>
            <issue>25</issue>
            <fpage>2582</fpage>
            <page-range>2582-90</page-range>
            <pub-id pub-id-type="pmid">17582068</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27298.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cunningham-Rundles</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Maglione</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Common variable immunodeficiency.</article-title>
            <source>J Allergy Clin Immunol</source>
            <year>2012</year>
            <month>May</month>
            <volume>129</volume>
            <issue>5</issue>
            <fpage>1425</fpage>
            <page-range>1425-1426.e3</page-range>
            <pub-id pub-id-type="pmid">22541363</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27298.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cunningham-Rundles</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Primary B-cell immunodeficiencies.</article-title>
            <source>Hum Immunol</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>80</volume>
            <issue>6</issue>
            <fpage>351</fpage>
            <page-range>351-362</page-range>
            <pub-id pub-id-type="pmid">30359632</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
